Список литературы к статье Б.А.Татарского, С.В.Попова, Н.В.Казеновой

Фибрилляция предсердий и сердечная недостаточность:

подходы к антитромботической терапии

1. Andrew P. Ambrosy., Gregg C. Fonarow., Javed Butler., Ovidiu Chioncel., Stephen J. Greene., Muthiah Vaduganathan., Savina Nodari., Carolyn S.P. Lam., Naoki Sato., Ami N. Shah., Mihai Gheorghiade. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123–33
2. Maggioni A.P., Dahlstrom U., Filippatos G., Chioncel O., Crespo Leiro M., Drozdz J., Fruhwald F., Gullestad L., Logeart D., Fabbri G., Urso R., Metra M., Parissis J., Persson H., Ponikowski P., Rauchhaus M., Voors A. A., Nielsen O.W., Zannad, F., Tavazzi L. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2013;15:808–17.
3. Rewiuk K., Wizner B., Fedyk-Lukasik M., Zdrojewski T., Opolski G., Dubiel J. Epidemiology and management of coexisting heart failure and atrial fibrillation in an outpatient setting. Pol Arch Med Wewn 2011;121:392–9
4. Levy D., Kenchaiah S., Larson M.G., Benjamin E., Kupka M., Ho KKL., Murabito J., Vasan R. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-1402.
5. Maisel W. H; Stevenson, L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology and rationale for therapy. Am. J. Cardiol*.* 2003;91: 2D–8D
6. Chiang C., Naditch-Brule L., Murin J., Goethals M., Inoue H., O’Neill J., Silva-Cardoso J., Zharinov O., Gamra H., Alam S., Ponikowski P., Lewalter T., Rosenqvist M., Steg P. Distribution and risk profile of paroxysmal, persistent and permanent atrial fibrillation in routine clinical practice: insight from the real life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632–639
7. Thomas J. Wang., Martin G. Larson., Daniel Levy., Ramachandran S. Vasan., Eric P. Leip., Philip A. Wolf., Ralph B. D’Agostino., Joanne M. Murabito., William B. Kannel and Emelia J. Benjamin. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107:2920-2925.
8. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators.N Engl J Med 1992;327:685–91.
9. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N. Engl. J. Med*.* 1987**;**316**:**1429–1435.
10. Yoko Miyasaka**.**, Marion E. Barnes**.**, Bernard J. Gersh**.**, Stephen S. Cha**.**, Walter Abhayaratna**.,** James B. Seward**.**, Toshiji Iwasaka**.**, Teresa S M Tsang**.** Incidence and mortality risk of congestive heart failure in atrial fibrillation patients: a community-based study over two decades. Eur. Heart J. 2006;27:936–941
11. Pederson O., Bagger H., Kober L., Torp-Pederson C; for the TRACE Study Group. Impact of congestive heart failure and left ventricular systolic function on the prognostic significance of atrial fibrillation and atrial flutter following myocardial infarction. Int J Cardiol. 2005; 100: 65 – 71.
12. Olsson L., Swedberg K., Ducharme A., Granger C., Michelson E., McMurray J., Puu M., Yusuf S., Pfeffer M. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction. J Am Coll Cardiol. 2006; 47: 1997 – 2004
13. Liang-Han Ling et al. Comorbidity of atrial fibrillation and heart failure. Nature Reviews Cardiology 2016;13:131–147
14. Lalani G., Schricker A., Gibson M., Rostamian A., Krummen D., Narayan S. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation. J Am Coll Cardiol 2012;59:595–606.
15. Healey J., Israel C., Connolly S., Hohnloser S., Nair G., Divakaramenon S., Capucci A., Van Gelder I., Lau C., Gold M., Carlson M., Themeles E., Morillo C. Relevance of electrical remodeling in human atrial fibrillation: results of the asymptomatic atrial fibrillation and stroke evaluation in pacemaker patients and the atrial fibrillation reduction atrial pacing trial mechanisms of atrial fibrillation study. Circ Arrhythm Electrophysiol 2012;5:626–631
16. Li D., Shinagawa K., Pang L., Leung T.K., Cardin S., Wang Z., Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001;104:2608–2614
17. Narayan S., Franz M., Clopton P., Pruvot E., Krummen D. Repolarization alternans reveals vulnerability to human atrial fibrillation. Circulation 2011;123:2922–2930
18. **Diagnosis and treatment of atrial fibrillation. Recommendations RSC, RSSA AND ACS, 2012.** Russian (Национальные рекомендации по диагностике и лечению фибрилляции предсердий (2012) под эгидой обществ-РКО , ВНОА и АССХ http://www.scardio.ru/rekomendacii/rekomendacii\_rko/nacionalnye\_rekomendacii\_po\_diagnostike\_i\_lecheniyu\_fibrillyacii\_predserdiy\_2012).
19. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016; 18:12–36
20. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS European Heart Journal doi:10.1093/eurheartj/ehw210
21. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure European Heart Journal. 2016. doi:10.1093/eurheartj/ehw128
22. Vemmos K., Ntaios G., Savvari P., Vemmou A., Koroboki E., Manios E.. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10-year follow-up study. Eur J Heart Fail 2012;14:211–8.
23. Magnani G., Giugliano R., Ruff C., [Murphy](http://circ.ahajournals.org/search?author1=Sabina+A+Murphy&sortspec=date&submit=Submit) S., [Nordio](http://circ.ahajournals.org/search?author1=Francesco+Nordio&sortspec=date&submit=Submit) N., [Rutman](http://circ.ahajournals.org/search?author1=Howard+Rutman&sortspec=date&submit=Submit) H., [Curt](http://circ.ahajournals.org/search?author1=Valentin+Curt&sortspec=date&submit=Submit) V., [Mercuri](http://circ.ahajournals.org/search?author1=Michele+Mercuri&sortspec=date&submit=Submit) M., Braunwald E., Antman E. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: Insights from Engage-AFTIMI 48. Circulation. 2014;130:Abstract 12680
24. Line Melgaard., Anders Gorst-Rasmussen., Deirdre Lane., Lars  Rasmussen., Torben  Larsen., G. H. Lip. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation JAMA.2015;314(10):1030-1038
25. Ziad Hijazi., Jonas Oldgren., Ulrika Anderssonc., Stuart J. Connolly., Michael D. Ezekowitz., Stefan H. Hohnloser., Paul A. Reilly., Dragos Vinereanu., Agneta Siegbahn., Salim Yusuf., Lars Wallentin. Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy. Circulation. 2012;125:1605-1616
26. Ziad Hijazi on behalf of the ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score forpredicting stroke in atrial fibrillation. European Heart Journal doi: 10.1093/eurheartj/ehw054
27. Pisters R., Lane DA., Nieuwlaat R., de Vos CB., Crijns HJ., Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100.
28. Hijazi Z on behalf of the ARISTOTLE and RE-LY Investigators. The novel biomarker based ABC (age, biomarkers, clinical history) bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016, 327(10035):2302-2311,
29. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67
30. Agarwal M, Apostolakis S, Lane DA, Lip GY. The impact of heart failure and left ventricular dysfunction in predicting stroke, thromboembolism, and mortality in atrial fibrillation patients: a systematic review. Clin Ther 2014;36:1135–1144.
31. De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013;110:1087–107
32. Fauchier L., Angoulvant D., Lip GY. The SAMe-TT2R2 score and quality of anticoagulationin atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. Europace 2015;17:671–3
33. Connolly SJ., Ezekowitz MD., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly PA., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., Lewis BS., Darius H., Diener HC., Joyner CD., Wallentin L. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med2009;361:1139–1151
34. Patel MR., Mahaffey KW., Garg J., Pan G., Singer DE., Hacke W., Breithardt G., Halperin JL., Hankey GJ., Piccini JP., Becker RC., Nessel CC., Paolini JF., Berkowitz SD., Fox KA., Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med2011;365:883–891
35. Granger CB., Alexander JH., McMurray JJ., Lopes RD., Hylek EM., Hanna M., Al-Khalidi HR., Ansell J., Atar D., Avezum A., Bahit MC., Diaz R., Easton JD., Ezekowitz JA., Flaker G., Garcia D., Geraldes M., Gersh BJ., Golitsyn S., Goto S., Hermosillo AG., Hohnloser SH., Horowitz J., Mohan P., Jansky P., Lewis BS., Lopez-Sendon JL., Pais P., Parkhomenko A., Verheugt FW., Zhu J., Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med2011;365:981–992
36. Giugliano RP., Ruff CT., Braunwald E., Murphy SA., Wiviott SD., Halperin JL., Waldo AL., Ezekowitz MD., Weitz JI., Spinar J., Ruzyllo W., Ruda M., Koretsune Y., Betcher J., Shi M., Grip LT., Patel SP., Patel I., Hanyok JJ., Mercuri M., Antman EM. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med2013;369:2093–2104
37. Ruff CT., Giugliano RP., Braunwald E,. Hoffman EB., Deenadayalu N., Ezekowitz MD., Camm AJ., Weitz JI., Lewis BS., Parkhomenko A., Yamashita T., Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–962.
38. Chan N., Paikin J., Hirsh J., Lauw M., Eikelboom J., Ginsberg J. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions Thromb Haemost 2014;111:798—807
39. Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, Yusuf S, Wallentin L, Investigators RE-LY. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail 2013;15:1053–1061
40. van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6:740–747
41. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek L, Wojdyla DM, Wallentin L, Granger CB. ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail 2013;6:451–60
42. Qinmei Xiong, Yee Cheng Lau, Keitaro Senoo, Deirdre A. Lane, Kui Hong, Gregory Y.H. Lip.Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. European Journal of Heart Failure (2015) 17, 1192–1200
43. Gianluigi Savarese., Robert P. Giugliano., Giuseppe M.C. Rosano., John McMurray., Giulia Magnani., Gerasimos Filippatos., Santo Dellegrottaglie., Lars H. Lund., Bruno Trimarco., Pasquale Perrone-Filardi. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. A Meta-Analysis. J Am Coll Cardiol HF 2016 http://d x.doi.org/10.1016/j.jchf.2016.07.012
44. Nielsen PB., Lane DA., Rasmussen LH., Lip GY., Larsen TB. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol2015;104:418–429